ArticleBMC pharmacology & toxicology2026
Neuroprotective effects of Urolithin A and B in an intracerebroventricular streptozotocin-induced Alzheimer's-like model in rats.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Alzheimer’s disease (AD), a prevalent neurodegenerative disorder, is characterized by amyloid beta and tau protein aggregation, oxidative stress, and neuroinflammation. Urolithin A (Uro A) and Urolithin B (Uro B), known for their anti-inflammatory, antioxidant, and neuroprotective properties, are promising therapeutic candidates for AD. This study evaluated the effects of Uro A and Uro B on memory, anxiety-like behaviors, brain oxidative stress markers, and histopathological changes in male rats subjected to streptozotocin (STZ)-induced AD. Wistar rats were divided into eight groups (n = 7) and treated with Uro A or Uro B (10 or 20 mg/kg), memantine (positive control), or vehicle control for 14 days following intracerebroventricular STZ injection. Behavioral tests, biochemical analyses, and histological evaluations were conducted after six weeks. Modest improvements in memory performance were observed (p < 0.05) in the shuttle box test and reduced anxiety-like behaviors in the elevated plus-maze test. Biochemical analyses revealed decreased oxidative stress markers (malondialdehyde and hydroperoxides) and increased total antioxidant capacity (p < 0.05). Also, it seems that both compounds can reduce necrotic neurons and amyloid-like depositions in the hippocampus and cerebral cortex, and no adverse effects on the histology of the liver, kidney, pancreas, and testis were observed. These findings demonstrate the therapeutic potential of Uro A and Uro B in ameliorating cognitive deficits, oxidative stress, and neuronal damage in AD. Further studies are needed to explore the mechanisms underlying these effects and their applicability in clinical contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.